Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Journal of the European Academy of Dermatology and Venereology · 2025-06 · 39 (6) · 1163-1173
DOI: 10.1111/jdv.20547 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 17.02.2025. Verfasst von B King und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Protein Kinase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study.
Objectives
This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories in patients who received ritlecitinib 50 mg and rolled over from Phase 2b/3 into the ongoing, open‐label, Phase 3 ALLEGRO‐LT study to describe long‐term response patterns and associated baseline disease characteristics.
Methods
Patients aged ≥12 years with ≥50% scalp hair loss received ritlecitinib 50 mg once daily in both studies. SALT score trajectories from baseline to Month 24 were used to categorise patients as early (SALT score ≤20 at Week 24 and Months 12 and 24), middle (≤20 at Months 12 and 24) or late responders (≤20 by Month 24) or as partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement) or non‐responders (did not achieve 30% improvement). The proportions of patients achieving sustained response (achieved and maintained SALT score ≤20 at all subsequent available time points through Month 24) and complete response (SALT score 0 at ≥1 time point through Month 24) were evaluated. Multivariable logistic regression assessed variables associated with response.
Results
Of 191 patients treated with ritlecitinib 50 mg, 87 (45.5%) were responders (SALT score ≤20), 24 (12.6%) were partial responders, 24 (12.6%) were relapsers and 56 (29.3%) were non‐responders. Of 87 patients categorised as responders, 81 (93.1%) sustained their clinical response and 47 (46.0%) achieved complete response. Factors associated with treatment response included female sex and less extensive and shorter duration of hair loss.
Conclusions
Approximately 45% of patients were SALT score responders, with up to 11% requiring >1 year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration. ClinicalTrials.gov Registration ALLEGRO phase 2b/3 study (NCT03732807); ALLEGRO‐LT study (NCT04006457).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA.
- The Permanente Medical Group, Vallejo, California, USA.
- The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York, USA.
- Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel.
- The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Sinclair Dermatology, Melbourne, Victoria, Australia.
ORCID-Profile: B King, K Lo Sicco, R Sinclair, K Ezzedine
Förderung
- Pfizer
Zitieren
APA
King, B., Mirmirani, P., Lo Sicco, K., Ramot, Y., Sinclair, R., Asfour, L., Ezzedine, K., Paul, C., Ohyama, M., Edwards, R. A., Bonfanti, G., Kerkmann, U., Wajsbrot, D., Ishowo-Adejumo, R., Zwillich, S. H., & Lejeune, A. (2025). Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. Journal of the European Academy of Dermatology and Venereology, 39(6), 1163-1173. https://doi.org/10.1111/jdv.20547
Vancouver
King B, Mirmirani P, Lo Sicco K, Ramot Y, Sinclair R, Asfour L, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. Journal of the European Academy of Dermatology and Venereology. 2025;39(6):1163-1173. doi:10.1111/jdv.20547
BibTeX
@article{King2025,
author = {King, B and Mirmirani, P and Lo Sicco, K and Ramot, Y and Sinclair, R and Asfour, L and Ezzedine, K and Paul, C and Ohyama, M and Edwards, R A and Bonfanti, G and Kerkmann, U and Wajsbrot, D and Ishowo-Adejumo, R and Zwillich, S H and Lejeune, A},
title = {Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {6},
pages = {1163--1173},
doi = {10.1111/jdv.20547}
}
EUVIMED